American Journal of Psychiatry

Article	Citations
Treating Pathologies of the Will	278
Evaluating Associations Between Cannabis and Heroin Use	214
Broadening the Parameters of Clinical High Risk for Psychosis	173
2024 Annual Meeting: Presidential Address	166
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	156
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	153
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	139
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	122
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	117
Depression, Inflammation, and Postpartum Psychosis	113
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	110
Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions	108
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	106
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	106
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	101
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	94
Reconsidering the Interpretive Basis of Neural Efficiency as a Biomarker in Pediatric Anxiety: Response to Ai and Colleagues	90
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial	86
Correcting Overestimations in Self-Harm Visit Data	84
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	83
Correction to Poirot et al.	80
Corrigendum to Morley et al.	78
2024 Annual Meeting: CEO and Medical Director’s Address	76
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	75
The First Large GWAS Meta-Analysis for Postpartum Depression	74

Highlights From the Residents’ Journal: September 2024	73
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	70
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	69
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	68
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	68
Familial Risk of Postpartum Psychosis	66
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	65
New Insights Into Psychotic Disorders	62
Highlights From the Residents’ Journal: March 2026	61
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	58
Sex Differences in Psychiatric Comorbidity Among Adults With Substance Use Disorders	58
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	57
Suicide and the Menstrual Cycle	57
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	57
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	56
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	55
Trauma and Adverse Outcomes: Cause, Consequence, or Shared Vulnerability?	54
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	54
A Proposed Expansion of the Definition of Treatment-Resistant Schizophrenia	53
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	53
A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial	52
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	52
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	50
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	50
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	50
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	50
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	50
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	49
Toward Inclusive, Evidence-Based rTMS Care for Patients With Co-Occurring Substance Use Disorders: Response to Steele et al.	48
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	47
Biosocial Implications of Indigenous Trauma	46
Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia	46
Smoking Cessation Treatment: Still Seeking a New Approach?	45
Alcohol and the Etiology of Depression	44
Resting-State Functional Connectivity of the Amygdala and Hippocampus in PTSD: Results From the PGC-ENIGMA PTSD Working Group	44
Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies	43
Risk of Incident Psychosis and Mania With Prescription Amphetamines	43
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	43
From Crisis to Action: Psychiatry’s Ethical Imperative to Defend Transgender People’s Rights, Dignity, and Access to Care	42
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	42
Cannabis and Psychosis: Association, Subtype, or Separate Disorder?	42
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	41
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	41
Suicide in Black Females	41
Psilocybin: From Psychiatric Pariah to Perceived Panacea	41
Implantable Neuromodulation Devices in Psychiatry: Human Fidelity and Implementation Challenges	40
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	39
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	39
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	38
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	38

Development of the Next DSM —Learnings From the DSM-5 Experience	37
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	37
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	36
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	35
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	35
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	34
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	34
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	34
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	33
Correction to Baum et al.	33
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	32
When Will There Be Good News?	31
Beneath the Phenotypic Surface: Pleiotropy Shapes the Co-Occurrence of Alcohol Use Disorder and Psychopathology	31
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	31
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	31
Co-Use of Alcohol and Cannabis: How Are They Related?	31
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	31
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	30
Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments	30
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	30
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	30
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	30
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	30
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	29
Toward Precision Noninvasive Brain Stimulation	29
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	29
Doxycycline Use, Developmental Vulnerability, Patterns of Care, and Antibiotic Selection	28
2024 Articles of Import and Impact	28
Correction	28
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	27
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	27
Highlights From the Residents’ Journal: December 2024	27
Technology and Mental Health: State of the Art for Assessment and Treatment	26
Adolescent Suicidality and Depression, Premenstrual Dysphoric Disorder, and Safety Issues Related to Ketamine and Esketamine Treatment	26
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	26
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	26
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	26
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	26
Personalizing Brain Stimulation for Psychiatric Disorders: From Circuits to Closed-Loop Control	26
The Future of DSM : A Strategic Vision for Incorporating Socioeconomic, Cultural, and Environmental Determinants and Intersectionality	26
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them	25
Functional Connectivity Mapping for rTMS Target Selection in Depression	25
The Evolving ADHD Phenotype in the Externalizing Context	25
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	25
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon	25
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	25
Progress and Challenges in GxE Research on Depression	25
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	25
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	25
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	24
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	24
Antidepressants and Bipolar Disorder: The Plot Thickens	23
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	23
Vaccines as Immunotherapies for Substance Use Disorders	23
Gray Matter Iron and Neuromelanin in Psychosis: A Systematic Review and Meta-Analysis of MRI Studies	23
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	23
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	23
Focusing on Substance Use Disorders, Opioids, and Craving	22
Psychotropic Drug–Related Weight Gain and Its Treatment	22
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	22
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	22
Perinatal Mental Health: Advances and Opportunities	22
Neglect of Adverse Effects in Treatment Guidelines for Depression	22
Highlights From the Residents’ Journal: September 2023	22
Polygenic Risk Scores and Genetics in Psychiatry	21
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	21
Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	21
Don’t Throw the Baby Out With the Bathwater: A Need for Nuanced Practice and Additional Research on Telehealth Management of ADHD	21
Is It Time for a Universal Outcome Measure to Deliver on the Promises of Interventional Psychiatry?	21
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	20
Inner-Directed Therapy in MDMA-Assisted Psychotherapy	20
Go With the Flow: MOR(E) to Ketamine Than NMDA Receptor Antagonism	20
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	20
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	20
Proposal for Circadian Rhythms and Their Behavioral Outputs as Biomarkers in DSM-6 : Response to Cuthbert et al.	19
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	19
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	19
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	19
Reports to the Membership	19
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	19

Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	19
Schizophrenia and Doxycycline: Microbiome Mediator?	18
Disclosure of Editors’ Financial Relationships	18
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial	18
Reports to the Membership	18
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	17
Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	17
Highlights From the Residents’ Journal: June 2025	17
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	17
Intravenous Brexanolone for the Treatment of Posttraumatic Stress Disorder: A Case Report	16
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	16
Association Between Polygenic Risk Scores and Outcome of ECT	16
Putting the Amygdala and Hippocampus in PTSD to Rest	16
Psychosis Risk With Prescription Amphetamine	16
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	15
An Honest Reckoning With the Amygdala and Mental Illness	15
Treatment Patterns and Barriers to Care Among U.S. Adults With Co-Occurring Substance Use Disorder and Mental Illness	15
Treating Depression With Repetitive Transcranial Magnetic Stimulation: A Clinician’s Guide	15
Prospective Associations Between Structural Brain Development and Onset of Depressive Disorder During Adolescence and Emerging Adulthood	15
Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark	14
Drug Overdose Prevention: An Exercise in Optimism	14
Disclosure of Editors’ Financial Relationships	14
MDMA and MDMA-Assisted Therapy	14
Seeking New Solutions Addressing Structural Racism, Childhood Trauma, Suicidal Behaviors Across Sexual Orientations, and Postpartum Depression	14
Adolescent Substance Use and Suicidal Behavior, Internet Overuse, and Shared Genetics Between Problematic Alcohol Use and Other Psychiatric Comorbidities	14
What is the Link Between Substance-Induced Psychosis and Primary Psychotic Disorders?	13
Mechanism-Focused Randomized Controlled Trials in Youths: Another Step Uphill	13
The Importance and Limitations of Null Findings	13
Prevalence of Suicidal Ideation and Suicide Attempts by Race and Gender in Three Large U.S. Adolescent Cohorts	13
Psychopathology in Youth: Treatment, Parenting, and Intergenerational Transmission	13
Determinants of Nonspecific Response to Treatment in Randomized Controlled Trials of Major Depressive Disorder: A Narrative Review	13
Esketamine Treatment for Depression in Adults: Response to Price et al. and Canuso et al.	13
Can Cognitive-Behavioral Therapy Normalize Neural Function in Youths With Pediatric Anxiety Disorders? A Developmental Neuroscience Perspective	13
Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders	13
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis	13
Clarifying Confounder Variables and Cross-Sectional Power to Make Causal Conclusions About Race, Adversity, and Brain Differences: Response to Scheeringa	13
Grip Strength as a Marker of Resting-State Network Integrity and Well-Being in Early Psychosis	13
20 Years of Aberrant Salience in Psychosis: What Have We Learned?	13
Inequalities in the Incidence of Psychotic Disorders Among Racial and Ethnic Groups	13
Correction to Lebois et al.	13
The Psychiatric Bed Crisis in the United States: Understanding the Problem and Moving Toward Solutions	13